Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)

Clinical trial NCT05215106 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05215106
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Early Small (cT1N0) Triple Negative Breast Cancer

Start date: 2021-12-06
Primary completion: 2026-08-15
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.